Uniqure NV (NASDAQ:QURE) CEO Matthew C. Kapusta sold 39,169 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the sale, the chief executive officer now directly owns 439,764 shares in the company, valued at approximately $9,551,674.08. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Matthew C. Kapusta also recently made the following trade(s):
- On Thursday, January 4th, Matthew C. Kapusta sold 21,690 shares of Uniqure stock. The shares were sold at an average price of $19.87, for a total value of $430,980.30.
Shares of Uniqure stock traded down $0.79 on Monday, reaching $20.80. The company’s stock had a trading volume of 389,982 shares, compared to its average volume of 400,066. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure NV has a 52-week low of $4.72 and a 52-week high of $27.19. The company has a market cap of $684.06, a P/E ratio of -7.06 and a beta of 0.09.
QURE has been the topic of several recent analyst reports. HC Wainwright set a $35.00 price target on Uniqure and gave the company a “buy” rating in a research note on Tuesday, February 20th. Zacks Investment Research lowered Uniqure from a “hold” rating to a “sell” rating in a research note on Saturday, February 24th. BidaskClub raised Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, Janney Montgomery Scott initiated coverage on Uniqure in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $20.75.
A number of institutional investors and hedge funds have recently modified their holdings of QURE. OxFORD Asset Management LLP bought a new position in Uniqure in the 3rd quarter valued at $399,000. Mangrove Partners raised its position in shares of Uniqure by 167.4% during the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after acquiring an additional 66,763 shares during the last quarter. First Manhattan Co. bought a new stake in shares of Uniqure during the fourth quarter worth $1,371,000. SG Americas Securities LLC bought a new stake in shares of Uniqure during the fourth quarter worth $119,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Uniqure during the fourth quarter worth $1,298,000. Hedge funds and other institutional investors own 43.98% of the company’s stock.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.